Pages that link to "Q37463922"
Jump to navigation
Jump to search
The following pages link to Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma (Q37463922):
Displaying 45 items.
- Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma (Q26766240) (← links)
- Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities (Q26852437) (← links)
- Sunitinib in the treatment of metastatic renal cell carcinoma (Q28072057) (← links)
- The Human Kinome Targeted by FDA Approved Multi-Target Drugs and Combination Products: A Comparative Study from the Drug-Target Interaction Network Perspective (Q28553277) (← links)
- Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma (Q33408127) (← links)
- Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma (Q33668241) (← links)
- Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy. (Q33682981) (← links)
- Hypertension and hand-foot skin reactions related to VEGFR2 genotype and improved clinical outcome following bevacizumab and sorafenib (Q34036032) (← links)
- Pazopanib for the treatment of patients with advanced renal cell carcinoma (Q34207205) (← links)
- Angiotensin-2 receptors (AT1-R and AT2-R), new prognostic factors for renal clear-cell carcinoma? (Q34363440) (← links)
- VEGFR2 and Src kinase inhibitors suppress Andes virus-induced endothelial cell permeability (Q34741912) (← links)
- FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma (Q35583662) (← links)
- Retrospective Analysis of the Efficacy and Safety of Sorafenib in Chinese Patients With Metastatic Renal Cell Carcinoma and Prognostic Factors Related to Overall Survival (Q36153108) (← links)
- The Significance of Metastasectomy in Patients with Metastatic Renal Cell Carcinoma in the Era of Targeted Therapy (Q36204010) (← links)
- The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (Q36478715) (← links)
- Beyond anti-VEGF: dual-targeting antiangiogenic and antiproliferative therapy (Q36881812) (← links)
- Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma (Q37030920) (← links)
- Buccodental side effects of sunitinib in patients with metastatic renal cell carcinoma (Q37214287) (← links)
- Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients (Q37223221) (← links)
- Clinical impact of targeted therapies in patients with metastatic clear-cell renal cell carcinoma. (Q37616807) (← links)
- Pazopanib: a multikinase inhibitor with activity in advanced renal cell carcinoma (Q37752357) (← links)
- Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies? (Q37799821) (← links)
- New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib (Q37806966) (← links)
- Pazopanib for the treatment of renal cancer (Q37862259) (← links)
- Mechanisms of resistance to vascular endothelial growth factor blockade (Q37956587) (← links)
- Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities (Q37983389) (← links)
- A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma (Q38172644) (← links)
- Targeted therapies for renal cell carcinoma (Q39425380) (← links)
- Extension of overall survival beyond objective responses in patients with metastatic renal cell carcinoma treated with high-dose interleukin-2. (Q39699164) (← links)
- Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients. (Q39805218) (← links)
- Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma (Q41919666) (← links)
- Comparison of FDA Approved Kinase Targets to Clinical Trial Ones: Insights from Their System Profiles and Drug-Target Interaction Networks. (Q42195551) (← links)
- Long-term response of over ten years with sorafenib monotherapy in metastatic renal cell carcinoma: a case report (Q42670262) (← links)
- Anti-angiogenic therapies and hemorrhagic risk (Q43056786) (← links)
- Pazopanib for the Treatment of Non-Clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study (Q48792840) (← links)
- Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis. (Q49895116) (← links)
- Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism (Q50483056) (← links)
- Design, synthesis and biological evaluation of pazopanib derivatives as antitumor agents. (Q54403578) (← links)
- A phase II study of tandutinib (MLN518), a selective inhibitor of type III tyrosine receptor kinases, in patients with metastatic renal cell carcinoma. (Q54656049) (← links)
- Genetic variants of VEGFA and FLT4 are determinants of survival in renal cell carcinoma patients treated with sorafenib (Q58546862) (← links)
- Knockdown of LETM1 inhibits proliferation and metastasis of human renal cell carcinoma cells (Q58572715) (← links)
- Pathway Based Analysis of Mutation Data Is Efficient for Scoring Target Cancer Drugs (Q61811125) (← links)
- Tubulocystic renal cell carcinoma: is there a rational reason for targeted therapy using angiogenic inhibition? Analysis of seven cases (Q85849574) (← links)
- Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment (Q86445510) (← links)
- Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma (Q96811975) (← links)